Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 4/20 | 0.35 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23423085 | 0.96 | ZDHHC7 (0.39) | CA1CA2MIFZDHHC7SMN1; SMN2 | |
| SCHEMBL4907463 | 0.91 | CA2 (0.50) | CA1CA2MIFZDHHC7MAPT | |
| SCHEMBL10451509 | 0.91 | CA2 (0.50) | CA1CA2MIFZDHHC7MAPT | |
| SCHEMBL20361871 | 0.91 | CA2 (0.50) | CA1CA2MIFZDHHC7MAPT | |
| SCHEMBL11451874 | 0.88 | ZDHHC7 (0.53) | CA1CA2ZDHHC7MAPTHSD17B10 | |
| SCHEMBL20713284 | 0.88 | CPB2 (0.37) | CA1CA2MIFZDHHC7 | |
| SCHEMBL11437950 | 0.88 | ZDHHC7 (0.53) | CA1CA2ZDHHC7MAPTHSD17B10 | |
| SCHEMBL9245515 | 0.87 | CA2 (0.44) | CA1CA2MIFZDHHC7MAPT | |
| SCHEMBL27212164 | 0.86 | CA1 (0.40) | CA1CA2MIFZDHHC7SMN1; SMN2 | |
| SCHEMBL27461791 | 0.86 | MIF (0.45) | CA1CA2MIFZDHHC7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11118001-B2 | Isocyanate composition, method for producing isocyanate composition, and method for producing isocyanate polymer | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-14 | — | — | US | disclosed |
| US-11078321-B2 | — | — | 2021-08-03 | — | — | US | disclosed |
| US-20200048403-A1 | ISOCYANATE COMPOSITION, METHOD FOR PRODUCING ISOCYANATE COMPOSITION, AND METHOD FOR PRODUCING ISOCYANATE POLYMER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078321-B2 | — | IDH3A, IPO4, F12 | CA1 123/4885CA2 193/4885MIF 3524/4885 |
| US-11118001-B2 | Isocyanate composition, method for producing isocyanate composition, and method for producing isocyanate polymer | IDH3A, IPO4, IDH3B | CA1 90/4885CA2 164/4885MIF 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.